Hormone Therapy Timing for Prostate Cancer After Surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that was confirmed by a biopsy.
- After your prostate removal surgery, your PSA level was 0.1 or higher.
- Your doctor believes you are a candidate for salvage radiation therapy and hormone therapy (ADT).
- You are 18 years or older and able to understand and follow study instructions in English or Spanish.
- You have not already taken hormone therapy for rising PSA after surgery (unless your testosterone has recovered to normal levels).
- Your cancer has not spread to lymph nodes or bones outside the pelvis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a drug called apalutamide (combined with hormone therapy) after prostate removal helps prevent the cancer from returning. It is for men whose prostate cancer has a high risk of coming back after surgery.
This trial compares two lengths of hormone treatment (androgen deprivation therapy) given around “salvage” radiation after prostate surgery for rising PSA. It aims to see which schedule works best to control prostate cancer while keeping side effects manageable.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This study looks at combining radiotherapy and hormone therapy after prostate surgery to improve outcomes for men with prostate cancer. It uses samples and data from the larger RADICALS trial to understand which treatments work best.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
Hear when a new Prostatectomy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.